<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Consilium Medicum</journal-id><journal-title-group><journal-title xml:lang="en">Consilium Medicum</journal-title><trans-title-group xml:lang="ru"><trans-title>Consilium Medicum</trans-title></trans-title-group><trans-title-group xml:lang="zh"><trans-title>Consilium Medicum</trans-title></trans-title-group></journal-title-group><issn publication-format="print">2075-1753</issn><issn publication-format="electronic">2542-2170</issn><publisher><publisher-name xml:lang="en">Consilium Medicum</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">690188</article-id><article-id pub-id-type="doi">10.26442/20751753.2025.8.203403</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>Articles</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>Статьи</subject></subj-group><subj-group subj-group-type="article-type"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title xml:lang="en">Quality of life in patients with hypersensitivity pneumonitis in real clinical practice</article-title><trans-title-group xml:lang="ru"><trans-title>Качество жизни пациентов с гиперчувствительным пневмонитом в реальной клинической практике</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-9661-7213</contrib-id><name-alternatives><name xml:lang="en"><surname>Suvorova</surname><given-names>Olga A.</given-names></name><name xml:lang="ru"><surname>Суворова</surname><given-names>Ольга Александровна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>Assistant</p></bio><bio xml:lang="ru"><p>ассистент кафедры пульмонологии Института клинической медицины им. Н.В. Склифосовского</p></bio><email>olga.a.suvorova@mail.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-0685-4133</contrib-id><name-alternatives><name xml:lang="en"><surname>Trushenko</surname><given-names>Natalia V.</given-names></name><name xml:lang="ru"><surname>Трушенко</surname><given-names>Наталья Владимировна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>Cand. Sci. (Med.)</p></bio><bio xml:lang="ru"><p>кандидат медицинских наук, доц. кафедры пульмонологии, научный сотрудник Научно-методического центра мониторинга и контроля болезней органов дыхания</p></bio><email>olga.a.suvorova@mail.ru</email><xref ref-type="aff" rid="aff1"/><xref ref-type="aff" rid="aff2"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-1254-6863</contrib-id><name-alternatives><name xml:lang="en"><surname>Lavginova</surname><given-names>Baina B.</given-names></name><name xml:lang="ru"><surname>Лавгинова</surname><given-names>Баина Баатровна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>Resident</p></bio><bio xml:lang="ru"><p>ординатор кафедры пульмонологии</p></bio><email>olga.a.suvorova@mail.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-0928-2900</contrib-id><name-alternatives><name xml:lang="en"><surname>Levina</surname><given-names>Iuliia A.</given-names></name><name xml:lang="ru"><surname>Левина</surname><given-names>Юлия Алексеевна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>Resident</p></bio><bio xml:lang="ru"><p>ординатор кафедры пульмонологии</p></bio><email>olga.a.suvorova@mail.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-3174-5000</contrib-id><name-alternatives><name xml:lang="en"><surname>Merzhoeva</surname><given-names>Zamira M.</given-names></name><name xml:lang="ru"><surname>Мержоева</surname><given-names>Замира Магомедовна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>Cand. Sci. (Med.)</p></bio><bio xml:lang="ru"><p>кандидат медицинских наук, доц. кафедры пульмонологии</p></bio><email>olga.a.suvorova@mail.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-5999-2150</contrib-id><contrib-id contrib-id-type="spin">1645-5524</contrib-id><name-alternatives><name xml:lang="en"><surname>Avdeev</surname><given-names>Sergey N.</given-names></name><name xml:lang="ru"><surname>Авдеев</surname><given-names>Сергей Николаевич</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>D. Sci. (Med.), Prof., Acad. RAS</p></bio><bio xml:lang="ru"><p>акад. РАН, доктор медицинских наук, профессор, зав. кафедры пульмонологии, директор Национального медицинского исследовательского центра по профилю «Пульмонология», вед. научный сотрудник ФГБУ «НИИ пульмонологии», гл. внештатный специалист-пульмонолог Минздрава России</p></bio><email>olga.a.suvorova@mail.ru</email><xref ref-type="aff" rid="aff1"/><xref ref-type="aff" rid="aff2"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">Sechenov First Moscow State Medical University (Sechenov University)</institution></aff><aff><institution xml:lang="ru">ФГАОУ ВО «Первый Московский государственный медицинский университет им. И.М. Сеченова» Минздрава России (Сеченовский Университет)</institution></aff></aff-alternatives><aff-alternatives id="aff2"><aff><institution xml:lang="en">Federal Pulmonology Research Institute</institution></aff><aff><institution xml:lang="ru">ФГБУ «Научно-исследовательский институт пульмонологии» ФМБА России</institution></aff></aff-alternatives><pub-date date-type="pub" iso-8601-date="2025-09-07" publication-format="electronic"><day>07</day><month>09</month><year>2025</year></pub-date><volume>27</volume><issue>8</issue><issue-title xml:lang="en">Outpatient issues</issue-title><issue-title xml:lang="ru">Поликлинические вопросы</issue-title><fpage>488</fpage><lpage>494</lpage><history><date date-type="received" iso-8601-date="2025-09-07"><day>07</day><month>09</month><year>2025</year></date><date date-type="accepted" iso-8601-date="2025-09-07"><day>07</day><month>09</month><year>2025</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 2025, Consilium Medicum</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; 2025, ООО "Консилиум Медикум"</copyright-statement><copyright-year>2025</copyright-year><copyright-holder xml:lang="en">Consilium Medicum</copyright-holder><copyright-holder xml:lang="ru">ООО "Консилиум Медикум"</copyright-holder><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/"/><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/">https://creativecommons.org/licenses/by-nc-sa/4.0</ali:license_ref></license></permissions><self-uri xlink:href="https://consilium.orscience.ru/2075-1753/article/view/690188">https://consilium.orscience.ru/2075-1753/article/view/690188</self-uri><abstract xml:lang="en"><p><bold>Background</bold><bold>.</bold> Hypersensitivity pneumonitis (HP) is an immune-mediated interstitial lung disease that often progresses to pulmonary fibrosis, negatively affecting patients' quality of life (QOL).</p> <p><bold>Aim</bold><bold>.</bold> To assess QOL in patients with different HP phenotypes using the K-BILD and EQ-5D-5L questionnaires and identify clinical and functional factors affecting QOL.</p> <p><bold>Materials</bold><bold> and methods.</bold> The study included 105 HP patients [33 non-fibrotic (nfHP), 72 fibrotic (fHP), 32 with usual interstitial pneumonia (UIP) pattern on high-resolution computed tomography]. QOL, clinical data, respiratory function, echocardiography, dyspnea (mMRC scale), cough (VAS scale, LCQ), 6MWT results, and high-resolution computed tomography changes over 12 months were assessed. Statistical analysis involved nonparametric methods, correlation, linear, and multiple regression.</p> <p><bold>Results</bold><bold>.</bold> fHP and nfHP patients showed significant differences. fHP patients had a longer disease duration, more severe symptoms, lower lung function, and worse QOL. Those with fHP+UIP had worse lung function and more disease progression but similar QOL to fHP patients without UIP. For K-BILD, cough severity (LCQ), 6MWT distance, and forced vital capacity most affected QOL. For EQ-5D-5L, the 6MWT distance was the key factor.</p> <p><bold>Conclusion</bold><bold>.</bold> fHP patients experience a more severe disease course than nfHP patients. UIP pattern correlates with a more aggressive clinical progression. K-BILD and EQ-5D-5L are reliable tools for assessing QOL in HP. The greatest influence on QOL is exerted by the severity of cough, forced vital capacity and exercise tolerance.</p></abstract><trans-abstract xml:lang="ru"><p><bold>Введение.</bold> Гиперчувствительный пневмонит (ГП) – иммуноопосредованное интерстициальное заболевание легких, часто приводящее к легочному фиброзу, что ухудшает качество жизни (КЖ) пациентов.</p> <p><bold>Цель.</bold> Оценка КЖ у пациентов с различными фенотипами ГП с использованием опросников K-BILD и EQ-5D-5L и выявление клинических и функциональных параметров, значимо влияющих на КЖ.</p> <p><bold>Материалы и методы.</bold> В исследование включены 105 пациентов с ГП [33 – нефиброзный (нфГП), 72 – фиброзный (фГП), из них 32 – с паттерном обычной интерстициальной пневмонии (ОИП) по высокоразрешающей компьютерной томографии]. Кроме КЖ, оценивали демографические и клинические данные, параметры функции дыхания и эхокардиограммы, одышку по шкале mMRC и кашель по Визуальной аналоговой шкале и опроснику LCQ, результаты теста 6-минутной ходьбы (6МТХ), изменения по высокоразрешающей компьютерной томографии исходно и через 12 мес. Статистический анализ включал непараметрические методы сравнения 2 групп, корреляционный анализ, линейную и множественную регрессию.</p> <p><bold>Результаты.</bold> Пациенты с фГП характеризовались более длительным стажем заболевания, более выраженными симптомами, сниженной функцией легких и худшими показателями КЖ по шкалам K-BILD и EQ-5D-5L. При этом пациенты с фГП+ОИП демонстрировали худшие показатели функции легких, более длительное течение заболевания и более частое прогрессирование заболевания, однако не отличались по КЖ от пациентов с фГП без ОИП. По опроснику K-BILD наибольшее влияние на КЖ оказали выраженность кашля (LCQ), дистанция в 6МТХ и форсированная жизненная емкость легких. На индекс EQ-5D-5L наиболее значимое влияние оказывала дистанции 6МТХ.</p> <p><bold>Заключение.</bold> Пациенты с фГП и паттерном ОИП характеризуются более тяжелым течением заболевания по сравнению с нфГП. Опросники K-BILD и EQ-5D-5L можно считать надежными инструментами оценки КЖ при ГП. Наибольшее влияние на КЖ оказывают выраженность кашля, форсированная жизненная емкость легких и толерантность к физической нагрузке.</p></trans-abstract><kwd-group xml:lang="en"><kwd>interstitial lung diseases</kwd><kwd>hypersensitivity pneumonitis</kwd><kwd>quality of life</kwd><kwd>KBILD</kwd><kwd>EQ-5D-5L</kwd><kwd>LCQ</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>интерстициальные заболевания легких</kwd><kwd>гиперчувстительный пневмонит</kwd><kwd>качество жизни</kwd><kwd>K-BILD</kwd><kwd>EQ-5D-5L</kwd><kwd>LCQ</kwd></kwd-group><funding-group/></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><mixed-citation>Raghu G, Remy-Jardin M, Ryerson CJ, et al. Diagnosis of Hypersensitivity Pneumonitis in Adults. An Official ATS/JRS/ALAT Clinical Practice Guideline. Am J Respir Crit Care Med. 2020;202(3):e36-69. DOI:10.1164/rccm.202005-2032ST</mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation>Авдеев С.Н., Айсанов З.Р., Визель А.А., и др. Гиперчувствительный пневмонит: федеральные клинические рекомендации по диагностике и лечению. Пульмонология. 2025;35(1):16–41 [Avdeev SN, Aisanov ZR, Vizel AA, et al. Federal clinical guidelines on diagnosis and treatment of hypersensitivity pneumonitis. Pulmonologiya. 2025;35(1):16-41 (in Russian)]. DOI:10.18093/0869-0189-2025-35-1-16-41</mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation>Raghu G, Remy-Jardin M, Richeldi L, et al. Idiopathic Pulmonary Fibrosis (an Update) and Progressive Pulmonary Fibrosis in Adults: An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline. Am J Respir Crit Care Med. 2022;205(9):e18-47. DOI:10.1164/rccm.202202-0399ST</mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation>Adams TN, Batra K, Kypreos M, Glazer CS. Impact of radiographic honeycombing on transplant free survival and efficacy of immunosuppression in fibrotic hypersensitivity pneumonitis. BMC Pulm Med. 2023;23(1):224. DOI:10.1186/s12890-023-02523-3</mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation>Aronson KI, Rajan M, Varadarajan J, et al. Development and initial validation of a disease-specific instrument to measure health-related quality of life in hypersensitivity pneumonitis. ERJ Open Res. 2024;10(4):00155-2024. DOI:10.1183/23120541.00155-2024</mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation>Lubin M, Chen H, Elicker B, et al. A comparison of health-related quality of life in idiopathic pulmonary fibrosis and chronic hypersensitivity pneumonitis. Chest. 2014;145(6):1333-8. DOI:10.1378/chest.13-1984</mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation>Patel AS, Siegert RJ, Brignall K, et al. The development and validation of the King's Brief Interstitial Lung Disease (K-BILD) health status questionnaire. Thorax. 2012;67(9):804-10. DOI:10.1136/thoraxjnl-2012-201581</mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation>Cox IA, Campbell J, de Graaff B, et al. Assessment of health-related quality of life in Australian patients with idiopathic pulmonary fibrosis: a comparison of the EQ-5D-5L and the AHRQL-8D. Qual Life Res. 2023;32(2):473-93. DOI:10.1007/s11136-022-03205-z</mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation>Takei R, Matsuda T, Fukihara J, et al. Changes in patient-reported outcomes in patients with non-idiopathic pulmonary fibrosis fibrotic interstitial lung disease and progressive pulmonary fibrosis. Front Med (Lausanne). 2023;10:1067149. DOI:10.3389/fmed.2023.1067149</mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation>Birring SS, Prudon B, Carr AJ, et al. Development of a symptom specific health status measure for patients with chronic cough: Leicester Cough Questionnaire (LCQ). Thorax. 2003;58(4):339-43. DOI:10.1136/thorax.58.4.339</mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation>Stanojevic S, Kaminsky DA, Miller MR, et al. ERS/ATS technical standard on interpretive strategies for routine lung function tests. Eur Respir J. 2022;60(1):2101499. DOI:10.1183/13993003.01499-2021</mixed-citation></ref><ref id="B12"><label>12.</label><mixed-citation>Rautajoki T, Rantala HA, Sutinen E, et al. Health-related quality of life measured with K-BILD is associated with survival in patients with idiopathic pulmonary fibrosis. BMC Pulm Med. 2024;24(1):480. DOI:10.1186/s12890-024-03303-3</mixed-citation></ref><ref id="B13"><label>13.</label><mixed-citation>Omelyanovskiy V, Musina N, Ratushnyak S, et al. Valuation of the EQ-5D-3L in Russia. Qual Life Res. 2021;30(7):1997-2007. DOI:10.1007/s11136-021-02804-6</mixed-citation></ref><ref id="B14"><label>14.</label><mixed-citation>Hasan S, Verma A, Haque S, et al. A clinical study to monitor prescription patterns, clinical outcomes, and adverse drug reactions among patients of various interstitial lung diseases attending respiratory medicine outpatient department at tertiary care hospital in Northern India. Perspect Clin Res. 2024;15(3):141-6. DOI:10.4103/picr.picr_108_23</mixed-citation></ref><ref id="B15"><label>15.</label><mixed-citation>Lobo LJ, Liu Y, Li P, et al. Design and baseline characteristics of the ILD-PRO registry in patients with progressive pulmonary fibrosis. BMC Pulm Med. 2024;24(1):468. DOI:10.1186/s12890-024-03247-8</mixed-citation></ref><ref id="B16"><label>16.</label><mixed-citation>Julia-Serda G, Navarro-Esteva J, Doreste-Salgado L, et al. Survival and lung function changes in hypersensitivity pneumonitis according to radiological phenotypes compared with idiopathic pulmonary fibrosis. Cureus. 2024;16(3):e57307. DOI:10.7759/cureus.57307</mixed-citation></ref><ref id="B17"><label>17.</label><mixed-citation>Prior TS, Hilberg O, Shaker SB, et al. Validation of the King's Brief Interstitial Lung Disease questionnaire in idiopathic pulmonary fibrosis. BMC Pulm Med. 2019;19(1):255. DOI:10.1186/s12890-019-1018-0</mixed-citation></ref><ref id="B18"><label>18.</label><mixed-citation>D’Souza K, Ravichandran T, Venkatnarayan K, et al. Assessment of health-related quality of life in individuals with interstitial lung diseases in a tertiary care hospital in south India. Indian J Med Res. 2024;160(2):246-53. DOI:10.25259/IJMR_218_2024</mixed-citation></ref><ref id="B19"><label>19.</label><mixed-citation>Trushenko NV, Suvorova OA, Schmidt AE, et al. Updates on the Prevalence, Quality of Life, and Management of Chronic Cough in Interstitial Lung Diseases. Diagnostics. 2025;15(9):1139. DOI:10.3390/diagnostics15091139</mixed-citation></ref><ref id="B20"><label>20.</label><mixed-citation>Lee J, White E, Freiheit E, et al. Cough-specific quality of life predicts disease progression among patients with interstitial lung disease: data from the Pulmonary Fibrosis Foundation Patient Registry. Chest. 2022;162(3):603-13. DOI:10.1016/j.chest.2022.03.025</mixed-citation></ref><ref id="B21"><label>21.</label><mixed-citation>Khor YH, Johannson KA, Marcoux V, et al. Epidemiology and prognostic significance of cough in fibrotic interstitial lung disease. Am J Respir Crit Care Med. 2024;210(8):1035-44. DOI:10.1164/rccm.202311-2101OC</mixed-citation></ref><ref id="B22"><label>22.</label><mixed-citation>Glaspole IN, Chapman SA, Cooper WA, et al. Health-related quality of life in idiopathic pulmonary fibrosis: data from the Australian IPF Registry. Respirology. 2017;22(5):950-6. DOI:10.1111/resp.12989</mixed-citation></ref><ref id="B23"><label>23.</label><mixed-citation>Maqhuzu PN, Szentes BL, Kreuter M, et al. Determinants of health-related quality of life decline in interstitial lung disease. Health Qual Life Outcomes. 2020;18:334. DOI:10.1186/s12955-020-01570-2</mixed-citation></ref><ref id="B24"><label>24.</label><mixed-citation>Szentes BL, Kreuter M, Bahmer T, et al. Quality of life assessment in interstitial lung diseases: a comparison of the disease-specific K-BILD with the generic EQ-5D-5L. Respir Res. 2018;19(1):101. DOI:10.1186/s12931-018-0808-x</mixed-citation></ref></ref-list></back></article>
